Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Key facts

Sponsor

Protalix

Principal Investigator

Einat Almon, PhD

Protalix Ltd.

Intervention

PRX-112(drug)

Enrollment

16 target

Eligibility

18 years · All sexes

Timeline

2013 – 2014

Study locations (2)

• Rambam Medical Center, Haifa, Israel
• Shaare Zedek Medical Center, Jerusalem, Israel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gaucher disease

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGEARLY PHASE1NCT06528080
  A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease
  Shanghai Jiao Tong University School of Medicine
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06545136
  Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
  Spur Therapeutics
• ACTIVE NOT RECRUITINGNCT06488261
  Long Term Follow-Up for Safety of AVR-RD-02
  John Bernat
• RECRUITINGNANCT05992532
  GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
  Fundación Española de Hematología y Hemoterapía
• RECRUITINGNANCT05843552
  Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
  University of Minnesota
• RECRUITINGEARLY PHASE1NCT06272149
  An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
  Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• RECRUITINGPHASE1NCT05487599
  A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
  Prevail Therapeutics
• ACTIVE NOT RECRUITINGNCT05526664
  Omics Gaucher Study: Multiomic Approach
  CENTOGENE GmbH Rostock

See all trials for Gaucher disease →